Wenn Sie das Fenster schließen, wird Ihre Konfiguration nicht gespeichert, es sei denn, Sie haben Ihren Artikel in die Bestellung aufgenommen oder zu Ihren Favoriten hinzugefügt.
Klicken Sie auf OK, um das MILLIPLEX® MAP-Tool zu schließen oder auf Abbrechen, um zu Ihrer Auswahl zurückzukehren.
Wählen Sie konfigurierbare Panels & Premixed-Kits - ODER - Kits für die zelluläre Signaltransduktion & MAPmates™
Konfigurieren Sie Ihre MILLIPLEX® MAP-Kits und lassen sich den Preis anzeigen.
Konfigurierbare Panels & Premixed-Kits
Unser breites Angebot enthält Multiplex-Panels, für die Sie die Analyten auswählen können, die am besten für Ihre Anwendung geeignet sind. Unter einem separaten Register können Sie das Premixed-Cytokin-Format oder ein Singleplex-Kit wählen.
Kits für die zelluläre Signaltransduktion & MAPmates™
Wählen Sie gebrauchsfertige Kits zur Erforschung gesamter Signalwege oder Prozesse. Oder konfigurieren Sie Ihre eigenen Kits mit Singleplex MAPmates™.
Die folgenden MAPmates™ sollten nicht zusammen analysiert werden: -MAPmates™, die einen unterschiedlichen Assaypuffer erfordern. -Phosphospezifische und MAPmate™ Gesamtkombinationen wie Gesamt-GSK3β und Gesamt-GSK3β (Ser 9). -PanTyr und locusspezifische MAPmates™, z.B. Phospho-EGF-Rezeptor und Phospho-STAT1 (Tyr701). -Mehr als 1 Phospho-MAPmate™ für ein einziges Target (Akt, STAT3). -GAPDH und β-Tubulin können nicht mit Kits oder MAPmates™, die panTyr enthalten, analysiert werden.
.
Bestellnummer
Bestellinformationen
St./Pkg.
Liste
Dieser Artikel wurde zu Ihren Favoriten hinzugefügt.
Wählen Sie bitte Spezies, Panelart, Kit oder Probenart
Um Ihr MILLIPLEX® MAP-Kit zu konfigurieren, wählen Sie zunächst eine Spezies, eine Panelart und/oder ein Kit.
Custom Premix Selecting "Custom Premix" option means that all of the beads you have chosen will be premixed in manufacturing before the kit is sent to you.
Catalogue Number
Ordering Description
Qty/Pack
List
Dieser Artikel wurde zu Ihren Favoriten hinzugefügt.
Spezies
Panelart
Gewähltes Kit
Menge
Bestellnummer
Bestellinformationen
St./Pkg.
Listenpreis
96-Well Plate
Menge
Bestellnummer
Bestellinformationen
St./Pkg.
Listenpreis
Weitere Reagenzien hinzufügen (MAPmates erfordern die Verwendung eines Puffer- und Detektionskits)
Menge
Bestellnummer
Bestellinformationen
St./Pkg.
Listenpreis
48-602MAG
Buffer Detection Kit for Magnetic Beads
1 Kit
Platzsparende Option Kunden, die mehrere Kits kaufen, können ihre Multiplex-Assaykomponenten in Kunststoffbeuteln anstelle von Packungen erhalten, um eine kompaktere Lagerung zu ermöglichen.
Dieser Artikel wurde zu Ihren Favoriten hinzugefügt.
Das Produkt wurde in Ihre Bestellung aufgenommen
Sie können nun ein weiteres Kit konfigurieren, ein Premixed-Kit wählen, zur Kasse gehen oder das Bestell-Tool schließen.
Anti-HCV E2, clone AR3A, Cat. No. MABF2336, is a human recombinant monoclonal antibody that Hepatitis C virus E2 glycoprotein and is tested for use in ELISA and Neutralizing Activity.
More>>Anti-HCV E2, clone AR3A, Cat. No. MABF2336, is a human recombinant monoclonal antibody that Hepatitis C virus E2 glycoprotein and is tested for use in ELISA and Neutralizing Activity. Less<<
Empfohlene Produkte
Übersicht
Replacement Information
Description
Catalogue Number
MABF2336-100UL
Description
Anti-HCV E2 Antibody, clone AR3A
Alternate Names
Hepatitis C virus envelope protein
gp70
gp68
Background Information
Hepatitis C virus (HCV) is a small (~55-65 nm), enveloped, positive-sense single-stranded RNA virus that is a causative factor for hepatitis C and hepatocellular carcinoma. HCV expresses several proteins that promote viral replication. Genome polyprotein of HCV is a core protein that packages viral RNA to form a viral nucleocapsid, and promotes virion budding. It also modulates viral translation initiation by interacting with HCV IRES and 40S ribosomal subunit. It prevents the establishment of cellular antiviral state by blocking the interferon-alpha/beta (IFN-alpha/beta) and IFN-gamma signaling pathways and by inducing human STAT1 degradation. Envelope glycoproteins E1 (aa 192-383) and E2 (aa 384-746) of HCV are single-pass type I membrane proteins that form a heterodimer by non-covalent interaction of their transmembrane domains, which is involved in virus attachment to the host cell, virion internalization through clathrin-dependent endocytosis and fusion with host membrane. The C-terminal transmembrane domain of E1 and E2 acts as a signal sequence and forms a hairpin structure before cleavage by host signal peptidase. After cleavage, the membrane sequence is retained at the C-terminus of the protein, serving as ER membrane anchor. A reorientation of the second hydrophobic stretch occurs after cleavage producing a single reoriented transmembrane domain. The E2 antigenic site localized to amino acids 412-423 is reported to be highly conserved and is considered as an ideal target for cross neutralization of HCV genotypes. Clone AR1B is derived from Fab clone C11 and is shown to bind to soluble E2 and blocks E1E2 binding to CD81. (Ref.: Giang, E., et al. (2012). Proc. Natl. Acad. Sci. USA. 109(16); 6205-6210).
References
Product Information
Format
Purified
Presentation
Purified human recombinant recombinant monoclonal antibody in PBS without preservatives.
Anti-HCV E2, clone AR3A, Cat. No. MABF2336, is a human recombinant monoclonal antibody that Hepatitis C virus E2 glycoprotein and is tested for use in ELISA and Neutralizing Activity.
Key Applications
ELISA
Neutralizing
Application Notes
Neutralizing: A representative lot neutralized HCV isolates from multiple genotypes. (Giang, E., et. al. (2012). Proc Natl Acad Sci USA. 109(16):6205-10; Law, M., et. al. (2008). Nat Med. 14(1):25-7).
ELISA Analysis: A representative lot detected HCV E2 in ELISA applications (Giang, E., et. al. (2012). Proc Natl Acad Sci USA. 109(16):6205-10; Law, M., et. al. (2008). Nat Med. 14(1):25-7).
Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user
Biological Information
Immunogen
Antibody Fab fragment C1 expressed in E. coli, purified, and converted into full-length IgG1 molecule in CHO-K1 cells.
Epitope
Discontinuous; E2
Clone
AR3A
Concentration
0.5 mg/mL. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.
Host
Human Recombinant
Specificity
Clone AR3A is a human recombinant antibody produced from Fab fragment C1, expressed in E.coli and converted into full-length IgG1 in CHO-K1 cells. It detects E2 envelope protein in Hepatitis C virus.
Evaluated by ELISA in lysate from HEK293T cells transfected with H77E1E2.
ELISA Analysis: A x/2 Dilution of this antibody detected Hepatitis C virus E2 glycoprotein in HEK293T cells transfected with H77E1E2, but not in control cell lysate.
Usage Statement
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Storage and Shipping Information
Storage Conditions
Stable for 1 year at -10°C to -25°C from date of receipt. Handling Recommendations: Upon receipt and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.
Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus Erick Giang 1 , Marcus Dorner, Jannick C Prentoe, Marlène Dreux, Matthew J Evans, Jens Bukh, Charles M Rice, Alexander Ploss, Dennis R Burton, Mansun Law Proc Natl Acad Sci U S A
109(16)
6205-10
2011
Hepatitis C virus (HCV) infects ∼2% of the world's population. It is estimated that there are more than 500,000 new infections annually in Egypt, the country with the highest HCV prevalence. An effective vaccine would help control this expanding global health burden. HCV is highly variable, and an effective vaccine should target conserved T- and B-cell epitopes of the virus. Conserved B-cell epitopes overlapping the CD81 receptor-binding site (CD81bs) on the E2 viral envelope glycoprotein have been reported previously and provide promising vaccine targets. In this study, we isolated 73 human mAbs recognizing five distinct antigenic regions on the virus envelope glycoprotein complex E1E2 from an HCV-immune phage-display antibody library by using an exhaustive-panning strategy. Many of these mAbs were broadly neutralizing. In particular, the mAb AR4A, recognizing a discontinuous epitope outside the CD81bs on the E1E2 complex, has an exceptionally broad neutralizing activity toward diverse HCV genotypes and protects against heterologous HCV challenge in a small animal model. The mAb panel will be useful for the design and development of vaccine candidates to elicit broadly neutralizing antibodies to HCV.
Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge Mansun Law 1 , Toshiaki Maruyama, Jamie Lewis, Erick Giang, Alexander W Tarr, Zania Stamataki, Pablo Gastaminza, Francis V Chisari, Ian M Jones, Robert I Fox, Jonathan K Ball, Jane A McKeating, Norman M Kneteman, Dennis R Burton Nat Med
14(1)
25-7
2008
A major problem in hepatitis C virus (HCV) immunotherapy or vaccine design is the extreme variability of the virus. We identified human monoclonal antibodies (mAbs) that neutralize genetically diverse HCV isolates and protect against heterologous HCV quasispecies challenge in a human liver-chimeric mouse model. The results provide evidence that broadly neutralizing antibodies to HCV protect against heterologous viral infection and suggest that a prophylactic vaccine against HCV may be achievable.
